AtaiBeckley Inc. (NASDAQ:ATAI, XETRA:9VC) announced that it has been added to a series of major US equity benchmark indices, a move that is expected to increase its visibility among institutional investors and trigger buying from passive investment funds.

The clinical-stage biotechnology company announced that it joined the S&P Total Market Index, the S&P Completion Index and CRSP US benchmark indices, effective March 23, 2026.

The inclusion in CRSP indices, which underpin funds tracking more than $3 trillion in assets under management, is expected to result in mandatory position-building by passive funds.

The S&P Total Market Index covers nearly all US-listed equities, while the S&P Completion Index represents approximately 3,000 mid-, small-, and micro-cap companies not included in the S&P 500. Both are widely used by institutional investors and asset managers as benchmarks for passive investment strategies.

AtaiBeckley’s CEO Srinivas Rao said the additions reflect the company’s growing presence in US equity markets.

“Being added to the S&P Total Market Index, S&P Completion Index, and CRSP US benchmark indices reflects meaningful recognition of AtaiBeckley's enhanced presence in US equity markets, with the CRSP index alone tracking more than $3 trillion in passively managed assets,” he said.

Rao added that the inclusions build on AtaiBeckley’s prior addition to the Nasdaq Biotechnology Index in December 2025 and broaden its reach across index-tracking strategies.

“We see these additions as a natural progression as AtaiBeckley’s market profile grows alongside our advancing clinical pipeline,” he said, pointing to the anticipated Phase 3 initiation of its BPL-003 program in the second quarter.

The company said its BPL-003 Phase 3 program remains on track to begin in Q2 2026, while topline data from its VLS-01 Phase 2b study are expected in the second half of the year.